© 2025 Hawaiʻi Public Radio
Donate
Play Live Radio
Next Up:
0:00
0:00
0:00 0:00
Available On Air Stations
Give to HPR and keep local support firmly rooted. The greater our local support, the greater our strength and resilience to serve you and future generations. Tap to get started.

Limits of lecanemab, a new drug approved to treat Alzheimer's

Hawaiʻi Public Radio | By Catherine Cruz
Published January 11, 2023 at 4:35 PM HST
Plaques located in the gray matter of the brain are key indicators of Alzheimer's disease.
Matt York
/
AP
Dr. William Burke goes over a PET brain scan in 2018 at Banner Alzheimer's Institute in Phoenix.

Breakthrough, or not? On The Long View, we focused on the long road to finding the best way to treat Alzheimer's disease. Our Contributing editor Neal Milner joined us in-studio

Further reading:

Good overall look: "FDA approves Alzheimer’s drug lecanemab amid safety concerns"
A critic scientist’s experience: Essay by Rachael Neve
Silberner’s article: “The Reason There’s Been No Cure for Alzheimer’s”

This interview aired on The Conversation on Jan. 11, 2023. The Conversation airs weekdays at 11 a.m. on HPR-1.
Tags
The Conversation Neal Milner
Catherine Cruz
Catherine Cruz is the host of The Conversation. Contact her at ccruz@hawaiipublicradio.org.
See stories by Catherine Cruz
Related Stories